- Rapid Dose Therapautics (DOSE) has received the final installment of the Collaborative Research and Development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC)
- The company has partnered with McMaster University to develop an oral vaccine for COVID-19
- This final instalment of $120,000 will help to support the Rapid Dose and McMaster partnership
- Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation
- Shares in Rapid Dose Therapeutics Corp. (DOSE) are steady, trading at $0.51 per share
Rapid Dose Therapautics (DOSE) has partnered with McMaster University to develop an oral vaccine for COVID-19.
Today, Rapid Dose announced that it has received the final installment of the Collaborative Research and Development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC).
Research and development for the orally delivered vaccine candidate is ongoing, and this final instalment of $120,000 will help to support the Rapid Dose and McMaster partnership.
Mark Upsdell, CEO of Rapid Dose Therapeutics, commented on the funding.
“We appreciate the ongoing support received from the Canadian government through NSERC as we continue to drive this important research forward,” he said. “Global experts have called for a needle-free method of delivering vaccines for COVID-19 and many other diseases, and this research is paramount to supporting the commercialization of such an innovation.”
Dr. Alex Adronov, McMaster University’s research team lead, added, “This installment allows us to continue our efforts in creating oral thin-film therapeutics for a variety of applications, including incorporation of vaccine components for needle-free vaccination.”
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation.
The company’s flagship product QuickStrip™ is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients that are delivered quickly into the bloodstream.
Shares in Rapid Dose Therapeutics Corp. (DOSE) are steady, trading at $0.51 per share.
